ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

YS YS Biopharma Company Ltd

1.02
0.00 (0.00%)
17 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
YS Biopharma Company Ltd NASDAQ:YS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.02 1.02 1.07 0 01:00:00

YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference

05/09/2023 1:30pm

PR Newswire (US)


YS Biopharma (NASDAQ:YS)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more YS Biopharma Charts.

GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will participate in in Citi's 18th Annual Biopharma Conference from Tuesday, September 5 to Thursday, September 7, 2023.

(PRNewsfoto/YishengBio Co., Ltd)

Dr. David Shao, YS Biopharma Chief Executive Officer, and other members of the Company's management team will attend and will be available for one-on-one and small group meetings.

For more information on the conference, please contact your conference representative. Meeting requests may also be emailed to YSBiopharma.IR@icrinc.com.

About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.

Investor Relations Contacts
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-participate-in-participate-in-citis-18th-annual-biopharma-conference-301917440.html

SOURCE YS Biopharma Co., Ltd.

Copyright 2023 PR Newswire

1 Year YS Biopharma Chart

1 Year YS Biopharma Chart

1 Month YS Biopharma Chart

1 Month YS Biopharma Chart